Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
The first pilot study from India analyzing Covaxin-Covishield mixed doses
A toll-free helpline to be set up to help doctors and patients
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Subscribe To Our Newsletter & Stay Updated
